Brief: Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study
08/09/2026 13:13
BRIEF-Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study Sept 8 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical Co Ltd 6990.HK:
KELUN-BIOTECH'S PARTNER WINDWARD BIO ANNOUNCES POSITIVE PHASE 2 RESULTS OF SKB378/WIN378 IN ASTHMA, AND INITIATES PHASE 3 STUDY
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO - SKB378/WIN378 WELL TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO - WINDWARD BIO INITIATES PHASE 3 STUDY OF SKB378/WIN378 WITH TWO TWICE-YEARLY DOSES
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO - SECOND PHASE 3 TRIAL POLARIS-2 PLANNED TO BEGIN IN FIRST HALF OF 2027
Source text: ID:nPnb6ZvRwa
Further company coverage: 6990.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sichuan Kelun-Biotech Biopharmaceutical
See all newsBrief: Sichuan Kelun-Biotech Biopharmaceutical Subscribes To CZB Structured Deposit VI For RMB500 Mln
Brief: Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Accepts New Indication Application For SAC-TMT
Brief: Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results Of Skb378/Win378 In Asthma, And Initiates Phase 3 Study
China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals
Brief: Sichuan Kelun-Biotech Biopharmaceutical Posts HY Net Income Attributable Of RMB 388 MLN